Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Exploring the Efficacy and Mechanism of Accelerated High-Definition Transcranial Direct Current Stimulation (HD-tDCS) in the Treatment of Obsessive-compulsive Disorder

11 de novembro de 2026 atualizado por: Zhen Wang, Shanghai Mental Health Center

Exploring the Efficacy and Mechanism of Accelerated High-Definition Transcranial Direct Current Stimulation (HD-tDCS) in the Treatment of Obsessive-compulsive Disorder: A Randomized Controlled Trial

This study will evaluate the therapeutic effects of accelerated high-definition transcranial direct current stimulation (HD-tDCS) as adjunct to pharmacotherapy in obsessive-compulsive disorder (OCD) patients, and the underlying neural mechanism by EEG, MRI, TMS-EEG and cognitive tasks.

Visão geral do estudo

Descrição detalhada

The purpose of this study is to evaluate the clinical efficacy of accelerated high-definition transcranial direct current stimulation (HD-tDCS) targeting the orbitofrontal cortex (OFC) as an adjunct to pharmacotherapy in patients with obsessive-compulsive disorder (OCD), and to investigate its underlying neural mechanisms. Sixty patients with OCD receiving stable pharmacotherapy will be randomized to receive either active or sham HD-tDCS. Stimulation will be administered four times daily for five consecutive days, followed by a two-day break and another five consecutive days of treatment, for a total of 40 sessions. Before each stimulation session, symptom provocation will be conducted by a research assistant who has completed standardized training.

Symptom severity will be assessed at baseline and upon completion of the HD-tDCS intervention. Assessments conducted throughout the study will include the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), the Clinical Global Impression (CGI) scale, the Obsessive-Compulsive Inventory-Revised (OCI-R), the Beck Depression Inventory-II (BDI-II), the Beck Anxiety Inventory (BAI), the Childhood Trauma Questionnaire (CTQ), a side-effect questionnaire, and other study-specified measures. A trained investigator will administer clinician-rated measures and oversee the completion of self-report questionnaires. Participants will also undergo magnetic resonance imaging (MRI), electroencephalography (EEG), and transcranial magnetic stimulation combined with EEG (TMS-EEG).

The Iowa Gambling Task will be administered at baseline, upon completion of the HD-tDCS intervention, and at the one-month follow-up after intervention completion to assess decision-making performance. The probabilistic reversal learning task will be administered at baseline, after the first HD-tDCS session, upon completion of the intervention, and at the one-month follow-up to assess reversal learning and cognitive flexibility under probabilistic uncertainty.

Tipo de estudo

Intervencional

Inscrição (Estimado)

60

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China
        • Shanghai Mental Health Center

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 50 anos (Adulto)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Aged 18-50 years, of Han Chinese ethnicity, and right-handed.
  2. Meet the diagnostic criteria for obsessive-compulsive disorder (OCD) according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).
  3. Have a Yale-Brown Obsessive Compulsive Scale (Y-BOCS) total score ≥16.
  4. Have received at least one selective serotonin reuptake inhibitor (SSRI) at an adequate dose for an adequate duration. If currently taking medication, the dose must have been stable for at least eight weeks, and the medication type and dose must remain unchanged throughout the study.
  5. Have completed junior high school education or above.
  6. Provide informed consent.

Exclusion Criteria:

  1. Meet DSM-5 diagnostic criteria for a psychiatric disorder other than OCD, as assessed using the Structured Clinical Interview for DSM-5 (SCID-5).
  2. Have obsessive-compulsive symptoms severe enough to prevent completion of the required assessments and examinations.
  3. Have received electroconvulsive therapy (ECT), including modified ECT, within the past six months, or any other form of neuromodulation within the past two months.
  4. Have a serious medical condition or any medical condition that may precipitate seizures or increased intracranial pressure, including cardiovascular or respiratory diseases.
  5. Have a history of neurological disorders (e.g., epilepsy or stroke), traumatic brain injury, or brain surgery.
  6. Have implanted medical devices or materials, such as intracranial stents, cardiac pacemakers, coronary stents, or cochlear implants.
  7. Be at high risk of suicide.
  8. Be pregnant or planning to become pregnant in the near future.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Triplo

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Ativo: active HD-tDCS

Active cathodal high-definition transcranial direct current stimulation (HD-tDCS) targeting the right orbitofrontal cortex (OFC) will be administered four times daily at two-hour intervals for five consecutive days, followed by a two-day break and another five consecutive days of treatment, for a total of 40 sessions. Before each stimulation session, symptom provocation will be conducted by a research assistant who has completed standardized training.

The HD-tDCS device will deliver a direct current of 2 mA for 20 minutes per session. The cathode will be positioned at Fp2 to target the right orbitofrontal cortex (OFC), with four return anodes placed at Fpz, AFz, AF4, and AF8, according to the international 10-10 EEG electrode placement system.

Comparador Falso: sham HD-tDCS

Sham high-definition transcranial direct current stimulation (HD-tDCS) targeting the right orbitofrontal cortex (OFC) will be administered four times daily at two-hour intervals for five consecutive days, followed by a two-day break and another five consecutive days of treatment, for a total of 40 sessions. Before each stimulation session, symptom provocation will be conducted by a research assistant who has completed standardized training.

In the sham stimulation group, the current will be gradually ramped up to 2 mA over approximately 30 seconds at the beginning of each session and ramped down to 0 mA over approximately 30 seconds at the end of each session.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Symptom improvement assessed by the Yale-Brown Obsessive Compulsive Scale(Y-BOCS)
Prazo: About 6 weeks

The Yale-Brown Obsessive Compulsive Scale (Y-BOCS) is a semi-structured, clinician-rated instrument used to assess the severity of obsessive-compulsive symptoms. It comprises 10 items: five assessing obsessions and five assessing compulsions. Each item is rated on a five-point scale from 0 to 4, yielding a total score ranging from 0 to 40, with higher scores indicating greater symptom severity. Treatment response is defined as a reduction of at least 35% in the Y-BOCS total score from baseline to the end of the HD-tDCS intervention.

About 6 weeks

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
The Beck Depression Inventory-II (BDI-II)
Prazo: About 6 weeks

It is a 21-item self-report measure scored on a 4-point Likert-type scale to summarize recent symptoms of depression.The higher the score, the higher the level of depression.

About 6 weeks
The Beck Anxiety Inventory (BAI)
Prazo: About 6 weeks

It is a 21-item self-report inventory that is used for measuring the severity of anxiety.The higher the score, the higher the level of anxiety.

About 6 weeks
Side-effect questionnaire
Prazo: About 6 weeks

It consists of ten commonly-reported side effects as well as an "other" category that allows participants to describe experiences/sensations not otherwise covered to rate the intensity of side effects.

About 6 weeks

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

25 de outubro de 2026

Conclusão Primária (Estimado)

31 de outubro de 2029

Conclusão do estudo (Estimado)

31 de dezembro de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

11 de novembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

11 de novembro de 2026

Primeira postagem (Real)

17 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

17 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

11 de novembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • 20240XJQ03DCS

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever